Oral Peptide Delivery: Barriers, Strategies, and the Future of Non-Injectable Peptides

Most therapeutic peptides are administered by injection — subcutaneous, intramuscular, or intravenous. The reason is simple: the gastrointestinal tract is hostile to peptides. Oral delivery is the most convenient route for patient compliance, but achieving meaningful oral bioavailability for peptides remains one of the hardest problems in drug delivery.

The three barriers

Barrier 1: Gastric acid

The stomach maintains a pH of 1.5–3.5 — an environment that denatures most protein and peptide structures. Acid hydrolysis cleaves peptide bonds, particularly at aspartate and asparagine residues. The low pH also activates pepsin, the first major protease the peptide encounters.

Notable exception: BPC-157 is remarkably stable in gastric acid. As a fragment of a gastric juice protein, it evolved to function in this environment. Most therapeutic peptides did not.

Barrier 2: Enzymatic degradation

The GI tract contains a cascade of proteolytic enzymes:

• Pepsin (stomach, pH 1.5–3): Broad-specificity endopeptidase
• Trypsin and chymotrypsin (duodenum, pH 7–8): Cleave after basic and aromatic residues respectively
• Carboxypeptidases (pancreatic): Attack from the C-terminus
• Aminopeptidases (brush border): Attack from the N-terminus
• DPP-IV (brush border): Cleaves peptides with proline or alanine at position 2 — responsible for rapid degradation of native GLP-1 and GIP

Combined, these enzymes degrade most linear peptides within minutes of entering the small intestine. This is why native GLP-1 has a half-life of 2–3 minutes while DPP-IV-resistant analogs like semaglutide persist for days.

Barrier 3: Intestinal membrane permeability

Even if a peptide survives acid and enzymes, it must cross the intestinal epithelium — a single layer of columnar cells connected by tight junctions. Peptides face two permeability challenges:

• Transcellular: Most peptides are too large, too polar, and have too many hydrogen bond donors to passively diffuse across cell membranes. The "Rule of Five" predicts poor absorption for molecules with MW > 500 Da and > 5 H-bond donors — most therapeutic peptides violate both criteria.
• Paracellular: Tight junctions between enterocytes have a pore radius of ~4–8 Å, excluding molecules larger than ~200 Da. Peptides are too large for paracellular transport under normal conditions.

The combined result of all three barriers: oral bioavailability of unmodified peptides is typically < 1%.

Current solutions

Absorption enhancers (SNAC)

Sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC) is the absorption enhancer used in oral semaglutide (Rybelsus). SNAC works through multiple mechanisms:

• Local pH buffering: Creates a microenvironment around the peptide that protects against acid and pepsin
• Transient transcellular permeability enhancement: Promotes peptide absorption across gastric epithelial cells
• Peptide monomerization: Prevents aggregation of semaglutide, keeping it in the absorbable monomeric form

Oral semaglutide achieves ~1% bioavailability with SNAC — which sounds low but is sufficient for therapeutic effect because the dose can be increased (14 mg oral vs. 1 mg injectable weekly). This represents one of the most significant achievements in oral peptide delivery.

Enteric coating

Enteric coatings (pH-sensitive polymers like Eudragit) protect the peptide from gastric acid by dissolving only at intestinal pH (> 5.5). This bypasses Barrier 1 entirely but does not address enzymes or permeability.

Enteric coating is often combined with protease inhibitors (aprotinin, soybean trypsin inhibitor) and permeation enhancers to address all three barriers simultaneously.

Protease inhibitors

Co-formulated protease inhibitors can reduce enzymatic degradation in the GI lumen:

• Aprotinin: Broad-spectrum serine protease inhibitor
• Soybean trypsin inhibitor (SBTI): Inhibits trypsin and chymotrypsin
• EDTA/citric acid: Chelate calcium and zinc required by metalloprotease co-factors

The limitation: protease inhibitors must be present in sufficient local concentration at the absorption site and must not be absorbed systemically (where they could disrupt normal protease function).

Peptide modification for oral stability

Chemical modification of the peptide itself can improve oral survivability:

• D-amino acid substitution: Replace L-amino acids at protease-susceptible positions with their D-enantiomers. Proteases are stereospecific for L-amino acids.
• N-methylation: Methylation of backbone amide nitrogens reduces protease recognition and improves membrane permeability by reducing hydrogen bond donors. Cyclosporin A achieves oral bioavailability partly through extensive N-methylation.
• Cyclization: Removes free termini (blocking exopeptidases) and constrains conformation (reducing endopeptidase access).
• Non-natural amino acid incorporation: Amino acids not recognized by proteolytic enzymes.

Emerging technologies

Intestinal patches (mucoadhesive devices)

Microneedle patches or mucoadhesive wafers that adhere to the intestinal wall and deliver peptides directly through the mucosa — bypassing the lumen entirely. Early-stage devices have demonstrated oral insulin delivery in animal models with bioavailability approaching 50%.

Self-orienting millimeter-scale applicators (SOMA)

Inspired by the leopard tortoise's self-righting shell, SOMA devices orient themselves against the gastric wall and inject a solid peptide needle into the mucosa. Developed at MIT/Novo Nordisk, SOMA achieved oral delivery of insulin and semaglutide in animal studies. The gastric mucosa lacks sharp pain receptors, so the injection is not perceived.

Cell-penetrating peptides (CPP) as carriers

Short cationic peptides (TAT, penetratin, oligoarginine) that cross cell membranes can be conjugated to therapeutic peptides to ferry them across the intestinal epithelium. The challenge is achieving consistent, dose-proportional absorption without damaging the epithelial barrier.

Nanoparticle encapsulation

Polymeric nanoparticles (PLGA, chitosan, lipid nanoparticles) encapsulate the peptide payload, protecting it from degradation and facilitating transcytosis across the intestinal epithelium. Chitosan nanoparticles additionally open tight junctions transiently, enabling paracellular transport.

The oral bioavailability trade-off

Low oral bioavailability (~1%) means that oral peptide products require 10–50x higher doses than injectable equivalents. This has cost implications (more peptide per dose), formulation challenges (larger tablets), and variable absorption (food, gastric motility, and individual physiology all affect the 1% window significantly).

For this reason, oral delivery is currently viable only for peptides where higher dosing is affordable and dose variability is clinically tolerable. GLP-1 agonists meet both criteria — the therapeutic window is wide and manufacturing scale is sufficient. Most research peptides do not meet these criteria, which is why injection remains the standard route.